Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 3/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.41 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.41 |
| ▸ | CCKBR | P32239 | 3/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.41 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.38 |
| ▸ | PARK7 | Q99497 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663962 | 0.89 | ROCK2 (0.46) | ROCK2CCKBRCCKARIP6K1ROCK1 | |
| SCHEMBL6678968 | 0.89 | NR1H2 (0.49) | NR1H2NR1H3CCKBRALDH1A1KDM4E | |
| SCHEMBL6662847 | 0.89 | TSHR (0.41) | ROCK2NR1H2NR1H3CCKBRALDH1A1 | |
| SCHEMBL6681227 | 0.88 | PRKAG1 (0.39) | ROCK2NR1H2NR1H3CCKBRCCKAR | |
| SCHEMBL6680821 | 0.88 | ALDH1A1 (0.41) | NR1H2NR1H3ALDH1A1KDM4EHPGD | |
| SCHEMBL6680077 | 0.86 | NR1H2 (0.40) | NR1H2NR1H3CCKBRCCKARALDH1A1 | |
| SCHEMBL6685279 | 0.86 | NR1H2 (0.38) | ROCK2NR1H2NR1H3CCKBRCCKAR | |
| SCHEMBL6665581 | 0.85 | NNMT (0.43) | ROCK2MRGPRX4OPRK1 | |
| SCHEMBL6664500 | 0.81 | NR1H2 (0.41) | NR1H2NR1H3CCKBRALDH1A1KDM4E | |
| SCHEMBL6664679 | 0.80 | SMN1; SMN2 (0.51) | ROCK2ALDH1A1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | HICKS JAMES LESTER (US) | 2004-03-04 | — | — | US | disclosed |
| WO-2004014388-A1 | 6,6-FUSED HETEROARYL DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | WARNER-LAMBERT COMPANY LLC (US) | 2004-02-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043985-A1 | 6,6-Fused heteroaryl derivatives as matrix metalloproteinase inhibitors | MMP13, MMP26, MMP9 | ROCK2 38/4885NR1H2 374/4885NR1H3 597/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.